Novartis’ Biogeneric Pipeline Has Six Projects; Pricing Issues Are A Focus
Executive Summary
Novartis expects to file its second biosimilar application in the coming year, Sandoz CEO Andreas Rummelt stated during the Swiss drug maker's first quarter sales and earnings call April 24
You may also be interested in...
Governors Take Aim At FDA For Not Releasing Follow-On Biologics Guidances
A bipartisan group of four governors are accusing FDA of violating the Administrative Procedure Act by not issuing guidance documents on therapeutically equivalent versions of insulin and human growth hormone products
Governors Take Aim At FDA For Not Releasing Follow-On Biologics Guidances
A bipartisan group of four governors are accusing FDA of violating the Administrative Procedure Act by not issuing guidance documents on therapeutically equivalent versions of insulin and human growth hormone products
Sandoz To Seek Omnitrope Therapeutic Equivalence With Genotropin
Sandoz plans to submit additional data to FDA to establish therapeutic substitutability for its follow-on human growth hormone product Omnitrope
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: